The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus
- PMID: 15797963
- DOI: 10.1210/jc.2004-1977
The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus
Abstract
The single-nucleotide polymorphism A/G in the type 2 deiodinase (D2) gene predicts a threonine (Thr) to alanine (Ala) substitution at codon 92 (D2 Thr92Ala) and is associated with insulin resistance in obese patients. Here, this association was investigated in 183 patients with type 2 diabetes mellitus, using homeostasis model assessment. The median fasting plasma insulin in Ala/Ala individuals was significantly higher than in patients with Ala/Thr or Thr/Thr genotypes (19.6 vs. 12.0 vs. 14.8 mIU/ml, respectively; P = 0.004). Assuming a recessive model, the homeostasis model assessment index was higher in the Ala/Ala group when compared with Ala/Thr-Thr/Thr group (8.50 vs. 4.85, P = 0.003). Although this polymorphism has not been associated with changes in D2 kinetics as measured in HEK-293 cells transiently expressing D2 Thr92Ala, we investigated whether such association could be detected in human tissue samples. Remarkably, in thyroid and skeletal muscle samples from subjects homozygous for the Ala allele, D2 velocity was significantly lower than in subjects with Ala/Thr-Thr/Thr genotypes (P = 0.05 and 0.04, respectively). In conclusion, the A/G polymorphism is associated with greater insulin resistance in type 2 diabetes mellitus patients and with lower D2 velocity in tissue samples. These findings suggest that the D2-generated T(3) in skeletal muscle plays a role in insulin resistance.
Similar articles
-
Clinical significance of type 2 iodothyronine deiodinase polymorphism.Expert Rev Endocrinol Metab. 2018 Sep;13(5):273-277. doi: 10.1080/17446651.2018.1523714. Epub 2018 Sep 27. Expert Rev Endocrinol Metab. 2018. PMID: 30257587 Review.
-
The Type 2 Deiodinase Thr92Ala Polymorphism Is Associated with Worse Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.J Diabetes Res. 2016;2016:5928726. doi: 10.1155/2016/5928726. Epub 2016 Sep 29. J Diabetes Res. 2016. PMID: 27777960 Free PMC article. Review.
-
Type 2 deiodinase Thr92Ala polymorphism is associated with disrupted placental activity but not with dysglycemia or adverse gestational outcomes: a genetic association study.Fertil Steril. 2014 Mar;101(3):833-9. doi: 10.1016/j.fertnstert.2013.11.018. Epub 2013 Dec 17. Fertil Steril. 2014. PMID: 24355051
-
D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients.Obesity (Silver Spring). 2011 Apr;19(4):825-32. doi: 10.1038/oby.2010.231. Epub 2010 Oct 7. Obesity (Silver Spring). 2011. PMID: 20930717
-
The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density.J Bone Miner Res. 2010 Jun;25(6):1385-91. doi: 10.1002/jbmr.27. J Bone Miner Res. 2010. PMID: 20200941
Cited by
-
Determination of Frequency of Type 2 Deiodinase Thr92Ala Polymorphism (rs225014) in 131I-treated Differentiated Thyroid Cancer Patients Undertaking L-thyroxine (L-T4) Suppression Therapy.Indian J Nucl Med. 2024 Jan-Feb;39(1):24-28. doi: 10.4103/ijnm.ijnm_120_23. Epub 2024 Mar 27. Indian J Nucl Med. 2024. PMID: 38817730 Free PMC article.
-
The recent advances and future perspectives of genetic compensation studies in the zebrafish model.Genes Dis. 2022 Jan 5;10(2):468-479. doi: 10.1016/j.gendis.2021.12.003. eCollection 2023 Mar. Genes Dis. 2022. PMID: 37223518 Free PMC article. Review.
-
The Physiological Functions and Polymorphisms of Type II Deiodinase.Endocrinol Metab (Seoul). 2023 Apr;38(2):190-202. doi: 10.3803/EnM.2022.1599. Epub 2023 Apr 27. Endocrinol Metab (Seoul). 2023. PMID: 37150515 Free PMC article. Review.
-
A new approach for the treatment of subthreshold bipolar disorders: Targeted high dose levothyroxine and repetitive transcranial magnetic stimulation for mitochondrial treatment.Front Psychiatry. 2022 Oct 13;13:976544. doi: 10.3389/fpsyt.2022.976544. eCollection 2022. Front Psychiatry. 2022. PMID: 36311500 Free PMC article. Review.
-
Optimal Hormone Replacement Therapy in Hypothyroidism - A Model Predictive Control Approach.Front Endocrinol (Lausanne). 2022 Jun 24;13:884018. doi: 10.3389/fendo.2022.884018. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35813623 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous